Regulatory
FDA will highlight aging and longevity medicine in regulatory science agenda
FDA Chief Scientist Steven Kozlowski announced that early fiscal year 2027 updates to the FARS will address longevity medicine and aging.
News · Regulatory
News
What companies, regulators and the press said about aging biology this week, in our own words, with the source a tap away.
Yesterday
Regulatory2 sources
FDA officials outline approval pathways for longevity therapies at ARDD
Agency leadership described regulatory approaches for treatments targeting aging at ARDD 2026, marking longevity as an agency priority.